

Subject Index

Italic page numbers indicate figures; page number followed by “t” indicate tables.

A

Age, glial tumors and, 106
AKT/mTOR pathway inhibition, use in glial tumors, 110
Alkaline comet assay, 67
Altered consciousness, 53–54
Analgesia, pharmacological, 85–88
Anterior cervical decompression and fusion (ACDF), 203
Anterior interosseous nerve syndrome, 290
Anterolateral quadrant, 80
Anti-angiogenesis, glial tumors, 110–111
Anticonvulsants, subarachnoid aneurysm, 261–262
Antifibrinolytics, subarachnoid aneurysm, 260–261
Antigen-presenting cells, 345–346
Apoptosis, in degenerative disc disease, 23
Arteriovenous malformations (AVMs), 114–144
 anterior callosal, 131, 132
 brainstem, 134, 135
 cerebellar, 132–134, 134
 complications, 134–140, 139
 decision making, 115–118
 deep parasagittal, 129–131
 embolization, 121–122, 122, 123t
 embryology, etiology, and genetics, 114–115
 general surgical technique, 124–125
 intraventricular, 131, 133
 medial temporal, 125–126, 126, 127
 medial-temporal insular, 126–127, 128
 natural history, 115, 115t
 observation alone, 124
 postoperative outcomes, 119–120t
 radiosurgery, 120–121, 121t
 splenial-posterior third ventricular region, 129
 striato-capsulo-thalamic region, 132
 surgical approaches to deep lesions, 125–134
 surgical resection, 118–120
 Sylvian, 125, 126
 trigonal, 127–129, 129, 130
Ascending pathways, 80
Astrocytomas, 210, 210–212, 211, 212
Asymptomatic Carotid Atherosclerosis Study (ACAS), 217
Asymptomatic Carotid Stenosis, Stenting Versus Endarterectomy Trial (ACT I), 220

B

Bering, Edgar, 48–40, 50
Blood pressure, effects of DBS, 317–319, 319, 321
Brain glucose metabolism, 54, 54
Brain injury management, 295–299, 296t, 307–312
 areas of future development, 297–298, 297t
 three recent developments, 296–297
Brain tumors, low-grade, awake craniotomy in, 332–335, 333–334t
Brainstem, hemangioblastomas in, 327–328, 328, 329

Bryan cervical disc, 204–205, 205
Bureaucratic issues, training for neurosurgery students, 36

C

Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS), 217–218
Carotid artery stenting, 217–222
 high-risk registries, 217–219, 218t
Carotid disease, endovascular therapy, 193–194
Carotid endarterectomy (CEA), 217–222
 demographic and intraoperative parameters, 302t
 neurocognitive changes after, 301–306
 risk factors
 postop day 1, 303t
 postop day 30, 304t
Carotid Revascularization using Endarterectomy or Stenting Systems (CaRESS), 217, 219–220
Carotid Revascularization *versus* Stent Trial (CREST), 217, 220
Carpal tunnel syndrome, 285–287, 286
 failed, 287, 287
Catabolic enzymes, in degenerative disc disease, 22–23
Cavernomas, 212–214, 213, 214
Cell-based clinical trials, 90–91
Cell-based therapy, neuropathic pain, 88–90
Cell lines, glioblastoma treatment, 66
Cell proliferation, control of, 88
Central sensitization, 77, 83, 84
Central transmission and regulation, 78–80, 79
Cerebellum, hemangioblastomas in, 327, 328, 329
Cerebral aneurysms, 157–178
 etiology, 157–158
 growth and rupture, 158–159
 incidence, 157
 natural history, 159–161
 paraclinoid, 166–172
 pitfalls, complications, and prevention, 165–166, 165–166t
 practice patterns, 165
 technological advances, 174–175
 treatment, 161–165, 163
Cerebral metabolism, cerebral *versus* global, 295–296
Cerebral perfusion pressure-based management, brain injury, 297
Cerebrospinal fluid, pulsatility, 48–52
Cervical arthroplasty, 203–207
Cervicore, 206, 206
CHARITÉ Artificial Disc, 223–228, 224–227
Chemosensitization, gliomas, 345–351
Chou-Talalay analysis, 66
Chromaffin cell trials, 91
Chronic pain. *see* Pain
Clipping, subarachnoid aneurysm, 259
Coiling, subarachnoid aneurysm, 259
Comatose state, 54–55
Commissural myelotomy, 12
Computed tomography (CT), evaluation of AVMs, 116

Computer-assisted neurosurgery, 267–271
 Controversial entrapments, 288–290
 Controversial entrapment syndromes for painful conditions, 291–293
 Controversial superimposed entrapments, 290–291
 Convection-enhanced drug delivery (CED), 59–60, 60
 epilepsy, 183, 183
 Cordotomy, 12–15
 lower cervical percutaneous, 13
 percutaneous cervical, 13
 Cortical and spinal-brainstem modulation, 84–85
 Cortical pathways, affective attachment and, 80–81, 81
 Craniofacial injury, 307–312
 Craniotomy, awake, resection of low-grade brain tumors, 332–335, 333–334t
 Cubital tunnel syndrome, 287–288
 Cyclosporin A, neuroprotective therapy in TBI, 307–312, 309, 310
 Cytokines, in degenerative disc disease, 22–23
 Cytotoxicity, glioblastoma treatment, 66

D

Deep brain stimulation (DBS)
 bilateral, 181, 181
 controlling the cardiovascular system with, 316–323, 318t
 Deep ulnar nerve paralysis, 288, 288
 Degenerative disc disease (DDD), 18
 CHARITÉ Artificial Disc, 223
 Dendritic cells, 345–351
 GM responsiveness after vaccination, 349–350
 sensitization of glioma cells, 348, 348–349
 treatment of intracranial gliomas, 346–347, 347
 Deoxyribonucleic acid (DNA), repair proteins, 67–76
 Diabetic neuropathy, 290–291
 Dorsal column stimulation, 16
 Dorsolateral quadrant, 80
 DREZ procedure, 16

E

Electrodes, importance in DBS, 318–321, 321
 Emergency neurosurgical care, 298
 Endogenous opioids, 85
 Endothelin antagonists, subarachnoid aneurysm, 262
 Endovascular surgery, neurosurgeons and, 27
 Endovascular therapy, evolution and future directions, 191–195
 Ependymoma, 61
 cervical, 210, 210–212, 211
 Epidural steroid injection (ESI), in lumbar degenerative disc disease, 19
 Epilepsy
 bilateral deep brain stimulation, 181, 181
 convection-enhanced drug delivery, 183, 183
 endoscopic resection of HH, 179–180, 180
 focal cooling therapy, 183
 gamma knife radiosurgery for MTLE or HH, 180, 180–181
 responsive neurostimulation, 182, 182–183

 seizure detection software, 181, 181–182
 surgical therapy for, 179–144, 180
 Ethnicity, glial tumors and, 106
 Evidence-based medicine, performance of lumbar fusion, 279–284
 Extralemniscal myelotomy, 14–15

F

Failed back surgery syndrome
 spinal cord stimulation for axial low back pain, 275–277, 276
 spinal cord stimulation *versus* reoperation for, 272–274, 273
 Fascicular transfers, 186–187, 186–187
 Flow cytometry, 67
 Fluid management in neurosurgery, 247–250
 Focal cooling therapy, epilepsy, 183
 Food and Drug Administration (FDA)
 artificial discs, 20
 CHARITÉ Artificial Disc, 223–228, 224–227
 Fourth circulation, 48–52
 Functional neurosurgery, 27

G

GADD34
 after temozolomide treatment, 71–73, 73, 74
 DNA repair and synergy, 71
 Gamma knife radiosurgery, for MTLE or HH, 180–181
 Gender differences, glial tumors and, 106
 Gene-based therapy, neuropathic pain, 91–93
 Genetics, in degenerative disc disease, 23
 Genetic signatures, predicting patient outcome and, 60
 Gene transfer, experimental evidence for, 93–95
 Genotype-specific therapies, brain injury management, 298
 Geography, glial tumors and, 106
 Glasgow Coma Scale, 53–57
 Glial tumors, 106–113
 alternative delivery strategies, 111
 chemotherapy, 111
 epidemiology, 106–108
 experimental therapeutic approaches, 111
 imaging, 108–109
 molecular biology, 109–110
 origin, 109
 targeting cell signaling pathways, 110–111
 Glioblastoma multiforme (GM), 59
 responsiveness to chemotherapy after vaccination, 349–350
 Glioma cells
 HSV-temozolomide interaction, 68, 68–69, 69t
 sensitization after dendritic cell therapy, 348, 348–349
 Gliomas, 58–63
 chemosensitization of, 345–351
 endogenous neural precursors for, 336–344
 future, 61
 genetic signatures and predicting patient outcome, 60
 malignant, 60–61
 radium bomb, 58, 59
 stem cells and, 61, 62
 translational research, 154–156, 155, 156

Glucose, concentrations in TBI, 309
 Glutamate, levels in TBI, 308, 309

H

Hagen-Poiseuille equation, 239
 Harrington Rod construct, 229–230, 230
 Head injury, 53–57
 Hemangioblastomas, 212–214, 213, 214
 in Von Hippel-Lindau disease, 324–331, 325, 326, 327
 Hemodilution
 in cerebral ischemia, 238, 239
 choice of an ischemic model, 240–241, 241, 243*t*
 clinical experience, 246–247
 colloids *versus* crystalloids for, 241–243, 245
 with a hemoglobin substitute, 238–239
 improved experimental ischemic model, 243–244
 isovolemic *versus* hypervolemic, 239–240, 241–242
 mechanism of the effect of, 245–246
 optimal degree, 244
 optimal timing, 244–245
 Hemodynamic therapy, subarachnoid aneurysm, 261
 Hemoglobin substitution, hemodilution with, 238–239
 Hemorrhagic stroke, endovascular therapy, 191–192, 192
 Histone deacetylase inhibitors, glial tumors, 111
 Homogeneity and heterogeneity, Presidential Address, 1–9
 Hydrocephalus, 48–52, 49, 51
 Hypertonic saline, brain injury management, 297
 Hypothalamic hamartomas (HH)
 endoscopic resection, 179–180, 180
 gamma knife radiosurgery for, 180–181

I

Imaging, computer-assisted, 267–268
 Imaging in Carotid Angioplasty and Risk of Stroke (ICAROS), 220–221, 220*t*
 Immune surveillance protection, 89
 Immunohistochemistry, 67
 Intervertebral discs, lumbar
 aging, 22, 22
 healthy, 22, 22
 Intracranial hypertension, prophylaxis against, 295, 296
 Intradiscal electrothermal therapy (IDET), 18–19
 Intraoperative feedback, real-time, 268–269
 Intraoperative nerve action potential (iNAP) recording, 39, 40
 Intraspinal cord tumors, surgery, 209–216
 Ischemic stroke, endovascular therapy, 192–193, 193

K

Kineflex C, 206, 206

L

Lactate/glucose ratio, in TBI, 311
 Lactate/pyruvate ratio, in TBI, 311
 Legal issues, training for neurosurgery students, 36
 Limited myelotomy, 15–15

Long thoracic nerve palsy, 290, 290
 Low back pain
 axial, spinal cord stimulation for, 275–277, 276
 evidence-based medicine for lumbar fusion, 279–284
 lumbar degenerative disc, 18
 Lower cervical percutaneous cordotomy, 13, 13, 14*t*
 Lumbar degenerative disc, 18–25
 Lumbar fusion, guidelines for, 279–284
 Lumbar spine, degenerative cascade, 20–21, 21
 Lumbar spondylosis and stenosis, 21

M

Magnesium, subarachnoid aneurysm, 262
 Magnetic resonance imaging (MRI)
 evaluation of AVMs, 116
 MEG and, 58–59, 59
 Magnetic resonance spectroscopy (MRS), glial tumors, 108–109
 Magnetoencephalography (MEG), 58–59, 59
 Melzack-Wall gate theory, 15
 MEMS technology, 101–102, 102
 Mesial temporal lobe epilepsy (MTLE)
 gamma knife radiosurgery for, 180–181
 surgical approach for, 179
 Microsurgery, 38–39
 Microvascular decompression, for trigeminal neuralgia, 313
 Minimally conscious state, 54–55
 Motor evoked potentials (MEP), 209
 Motor racing
 pathology, 148–152, 149–151*t*
 physiology, 145–148, 146–148
 Multiple marginal smear biopsies, awake craniotomy in low-grade brain tumors, 332–335
 Myelotomy, 12, 14

N

Nerve conduction studies and imaging, 38, 38*t*
 Nerve conduits, 41
 Nerve grafts, 39–41
 Nerve injury and regeneration, 44–45, 45
 Nerve repair, emerging techniques, 185–190
 Nerve surgery, 38–47
 coaptation alternatives, 41
 complications, 43–44
 end-to-side repair, 42
 postoperative perspectives, 44
 spinal cord implantation, 42
 transfers, 42, 43*t*, 185–186, 186, 186*t*
 tumors, 42–43
 Nerve tubes, 187–188, 188
 Neural precursors
 age-induced recruitment of, 338–339, 339
 antitumor impact, 340–341, 341
 endogenous
 specific responses, 338, 338
 tropism in gliomas, 336–344, 337
 glioblastoma-induced differentiation, 340, 341

lesion-specific recruitment, 339–340, 340
 Neural prostheses, 270–271
 Neural stem cell, for cell-based therapy, 89–90
 Neurobiology, nerve injury and regeneration, 44–45, 45
 Neurocognitive changes, after carotid endarterectomy, 301–306
 Neuronavigation, 58–59, 59
 Neuropathic pain, 77
 cell-based therapy, 88–90
 Neuroprotective therapies, neurochemical analytes in TBI, 307–312
 Neurostimulation
 electrode design, 274–275, 274–275, 275t
 pain of spinal origin, 272–278
 Neurosurgical education, 26–37
 bureaucratic issues, 33
 legal issues, 33
 maintaining standards of training, 254–255, 255
 patient-physician interaction, 35–36
 professionalism and other aspects, 33–37
 provision of services, 253–254
 reduced work hours, 252–256
 rewards and pride of the profession, 37
 teacher-trainee relationship, 32–33
 United Kingdom and Ireland, 252–253, 253
 what makes a good teacher, 32
 Neurotization. *see* Nerve surgery, transfers
 NMDAR activation, 79, 79
 Nociception, physiological, 77
 Non-viral vectors, 91–92
 North American Symptomatic Endarterectomy Trial (NASCECT), 217
 Notch filter, 51, 51–52

O

Oncolytic herpes simplex virus, 67–76
 Oxygen (100%), neuroprotective therapy in TBI, 307–312, 310

P

Pain
 chronic
 cell- and gene-based approaches, 86–87, 87
 cell-based therapy, 88–90
 endogenous opioids, 85
 exogenous treatments, 85–86
 future directions, 95–96
 need for treatment, 85
 molecular mechanisms, 77–97
 spinal cord surgery for, 11–17, 14t
 Pain pathways, 12
 Pain transmission, functional anatomy of, 78, 78t
 Paraclinoid aneurysms, 166–172, 167, 171, 173
 Patient data, digital, 267
 Percutaneous cervical cordotomy, 13, 13
 Periaqueductal gray matter (PAD), 316
 Peripheral nerve entrapment syndrome, 285–294
 Peripheral sensitization, 77, 81–83, 82, 82t

 molecular mechanisms, 82
 Periventricular gray matter (PVG), 316
 perioperative stimulation, 316–317, 317
 Pharmacological analgesia, 85–88
 Piriformis syndrome, 292
 Plasmid, glioblastoma treatment, 66
 Polymerase chain reaction (PCR), real-time, 67
 Porous Coated Motion (PCM), 205, 205
 Posterior interosseous nerve syndrome, 289
 Posterolateral fusion, lumbar disc, 20
 Postresidency education, 31–32
 Presidential Address, 1–9
 Prestige LP, 204, 204
 Prestige ST, cervical disc replacement, 203, 203–204
 Prodisc-C cervical disc, 205, 205
 Professional artistry view (PA), professionalism, 34t
 Professionalism, 33–37, 34t
 Progenitor cells, for cell-based therapy, 89–90
 Pronator syndrome, 293
 Pseudomonas endotoxin TP38, 60, 60
 Pudendal nerve entrapment, 292
 Pyruvate, in TBI, 310

R

Radial tunnel syndrome, 292
 Radiotherapy, intraspinal cord tumors, 215–216
 Rapture and rupture in the liminal world, 196–202
 RAS/MAPK pathway inhibitors, use in glial tumors, 110
 Residency
 argument for longer, 29–31
 continuing postresidency education, 31–32
 improvement in, 26
 possible changes in, 28–29
 Responsive neurostimulation, 182, 183–183
 Rexed's lamina, 79
 RNA, small interfering (siRNA), 67
 Robotics, computer-assisted neurosurgery, 269–270

S

Seizure detection, 181, 181–182
 Sensitization, 81
 Sensory evoked potentials (SEP), 209
 Serum markers, brain injury management, 298
 Single-step growth curves, glioblastoma treatment, 67
 Spinal cord
 hemangioblastomas in, 328, 328–329, 330
 reimplantation of avulsed nerve roots, 42
 surgery for pain, 11–17, 14t
 Spinal cord stimulation, 16
 FBSS with axial low back pain, 275–277, 276
 pain of spinal origin, 272–278
 versus reoperation for FBSS, 272–274, 273
 Spinal deformity, 235–236
 Spinal entry zone interruption, 16
 Spinal fusion and stabilization, in modern neurosurgery, 27
 Spinal reconstruction, 229–237, 230

Spinal trauma and neoplasia, 235
 Spine, biomechanics, 98–105
 applications, 100–101, 101
 fundamentals, 98–99
 future, 100
 implants, 99
 implant (screw) fracture, 99
 laboratory, 99–100
 physical and biological sciences, 101–102
 pressure, 102–103, 103, 104
 strain, 103, 104
 three-point bending forces, 100
 wedge compression fracture, 99
 Spinomesencephalic tract, 80
 Spinoreticular neurons, 80
 Spinothalamic cordotomy, 12
 Statins, subarachnoid aneurysm, 262
 Stem cells, gliomas and, 61, 62
 Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE), 217, 219
 Steroids
 brain injury management, 297
 subarachnoid aneurysm, 262
 Subarachnoid hemorrhage (SAH), 257–266, 258*t*
 treatment, 259–264
 Subcapsular nerve entrapment, 288–289

T

Task-related activations, group statistical maps, 55
 Teacher-trainee relationship, 32–33
 Technical rational view (TR), professionalism, 34*t*
 Temozolomide, 67–76

cells treated with
 G207 growth, 70, 70–71
 G207 yield from, 70, 70
 DNA repair genes induced by, 70–71, 71
 HSV interaction in MGMT-expressing cells, 69–70, 69*t*, 70
 HSV interaction in MGMT-negative cells, 68, 68–69
 Third Circulation (Cushing), 48, 50
 Thoracic outlet syndrome, 291–292
 Topiramate, neuroprotective therapy in TBI, 307–312, 311
 Total disc replacement (TDR), lumbar disc, 20
 Transgenic peptides, 88–89
 Transient receptor potential (TRP) channel, 78
 Translational research, gliomas, 154–156, 155, 156
 Traumatic brain injury (TBI), 295–299, 296*t*
 neuroprotective therapies, 307–312
 Trigeminal neuralgia, retreatment, 313–315, 314, 314*t*
 Tyrosine kinase inhibitors, use in glial tumors, 110

U

University of Buffalo Neurosurgery Experience, 220

V

Vascular biology, 194
 Vegetative state, 54–55
 Viral vectors, 92–93
 Viruses, glioblastoma treatment, 66
 Von Hippel-Lindau disease
 hemangioblastomas in, 324–331
 McCormick scale, 325*t*
 von Recklinghausen's disease (VRD), 42